VaxigripTetra
Trials 7
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 01 trial | ||||||
| Phase 0 | NCT06831786 | Mar → May 2024 | COVID-19 | Prince of Songkla University | Completed | No outcome recorded |
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT06294262 | Jan → Sep 2024 | vaccinia | LiteVax BV | Unknown | No outcome recorded |
| Phase 32 trials | ||||||
| Phase 3 | NCT05739474 | Jan 2022 → Jun 2023 | influenza | St. Petersburg Research Institute of Vaccines and Sera | Unknown | No outcome recorded |
| Phase 3 | NCT02550197 | Sep 2015 → Apr 2016 | influenza | Sanofi Pasteur, a Sanofi Company | Completed | No outcome recorded |
| Phase 42 trials | ||||||
| Phase 4 | NCT06824779 | Dec 2025 overdue | — | University Hospital of Saint-Etienne | Active not recruiting | No outcome recorded |
| Phase 4 | NCT05585983 | Dec 2022 → May 2026 overdue | type 1 diabetes mellitus | Aarhus University Hospital | Recruiting | No outcome recorded |
| Phase not applicable1 trial | ||||||
| — | NCT06259487 | Sep 2023 → Jun 2024 | heart failure, influenza, respiratory syncytial virus infectious disease | Wroclaw Medical University | Unknown | No outcome recorded |
| Comparator or background therapy7 trials | ||||||
| Phase 2 | NCT05048589 Comparator | Oct 2021 → May 2022 | influenza | Tor Biering-Sørensen | Completed | No outcome recorded |
| Phase 2/3 | NCT03699839 Comparator | Oct 2018 → Aug 2020 | disease related to solid organ transplantation, influenza | Oriol Manuel | Completed | Met primary |
| Phase 3 | NCT05409612 Comparator | Nov 2022 → Apr 2023 | morbid obesity | Assistance Publique - Hôpitaux de Paris | Completed | No outcome recorded |
| Phase 3 | NCT04143451 Comparator | Oct 2019 → Sep 2022 | influenza | The University of Hong Kong | Unknown | No outcome recorded |
| Phase 4 | NCT06508437 Comparator | Oct 2024 | atherosclerosis, coronary artery disorder, inflammatory disease | University Hospital, Tours | Completed | No outcome recorded |
| Phase 4 | NCT06716567 Comparator | Nov 2020 → Nov 2023 | influenza | Centre Hospitalier Universitaire Saint Pierre | Completed | No outcome recorded |
| Phase 4 | NCT04523324 Comparator | Oct 2019 → Jan 2020 | influenza | Centers for Disease Control and Prevention | Completed | No outcome recorded |
Evidence & citations 6 cited values
Every value below carries the sentence it was read from. 15 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | VaxigripTetra | “The goal of this clinical trial is to assess tolerability, reactogenicity, safety and immunogenicity of the Flu-M Tetra vaccine as compared to the VaxigripTetra vaccine in...” NCT05739474 ↗13“VaxigripTetra® (Sanofi Pasteur, Lyon, France) is a quadrivalent split-virion inactivated influenza vaccine (IIV4) containing two B-lineage strains approved in the European...” PMID 28933625 ↗ Nov 2017 “In an open-label, prospective study, 105 patients received concurrent influenza (Vaxigrip Tetra, season 2023/2024, Sanofi) and RSV (Arexvy, GSK) vaccinations from September...” PMID 38531725 ↗ Mar 2024 “The control intervention consists in an intramuscular injection of one dose of VaxigripTetra®, the standard non-adjuvanted intramuscular influenza vaccine (as routinely done).” NCT03699839 ↗ “Flu vaccination by one of FLU vaccines in the french market : FluarixTetra® (GSK), VaxigripTetra® (Sanofi-Pasteur), Influvac Tetra® (VIATRIS MEDICAL)” NCT06824779 ↗ “Alpharix-Tetra®, Vaxigrip Tetra® and Influvac Tetra® were used as influenza vaccines in the 2020-2021, 2021-2022, and 2022-2023 seasons respectively.” NCT06716567 ↗ “Standard Dose QIV (15µg Hemagglutinin) - VaxigripTetra Suspension for injection, 0,5ml prefilled syringe” NCT06508437 ↗ “the standard-dose quadrivalent influenza vaccines Influvactetra® and Vaxigriptetra will be used” NCT05048589 ↗ “Intramuscular injection of VaxigripTetra with or without LiteVax Adjuvant” NCT06294262 ↗ “Administering a VaxigripTetra™” NCT06831786 ↗ |
| Known as | IIV4 | “VaxigripTetra® (Sanofi Pasteur, Lyon, France) is a quadrivalent split-virion inactivated influenza vaccine (IIV4) containing two B-lineage strains approved in the European...” PMID 28933625 ↗ Nov 2017 |
| Known as | Vaxigrip | “0.5 mL intramuscular dose of Vaxigrip” NCT04523324 ↗ |
| Known as | VaxigripTetra (inactivated split influenza vaccine) | “VaxigripTetra (inactivated split influenza vaccine)” NCT05739474 ↗ |
| Modality | Vaccine | “is a quadrivalent split-virion inactivated influenza vaccine” PMID 28933625 ↗ Nov 2017 |
| Route | Intramuscular | “0.5 mL, Intramuscular” NCT02550197 ↗ |